In late 2019, NIH worked quickly to create and act on a plan to address the COVID-19 pandemic. We prioritized research to study SARS-CoV-2, the virus that causes COVID-19, and developed tests, treatments, and vaccines to detect, treat, and prevent the disease, including support for communities that were hardest hit by the pandemic.

Below, you can explore our research priorities and related initiatives, stories, and topics. For more detailed information, read the complete NIH-Wide Strategic Plan for COVID-19 Research.

COVID-19 Research Priorities

NIH’s response plan includes five strategic priorities to guide COVID-19 programs and research. Each priority fueled the creation of one or more initiatives, which harness NIH’s infrastructure to speed up research and foster collaboration with academic and private institutions.

Priority 1

Improve our knowledge about the disease

We lead and support research to better understand SARS-CoV-2 and the short- and long-term health effects of COVID-19.

Featured Initiatives

Featured Story

Illustration of SARS-CoV-2

Researchers Identify Four Long COVID Categories

A study classifying Long COVID into four types can help health care providers better target treatments for a patient’s specific symptoms.

Keep Reading

Priority 2

Develop diagnostic tests

We support the development of new COVID-19 testing technology and develop strategies to quickly deliver tests to communities around the country.

Featured Initiative

Rapid Acceleration of Diagnostics (RADx®)

The RADx initiative speeds innovation in the development, commercialization, and implementation of COVID-19 testing technology.

Featured Story

Physician holding COVID test

NIH Launches Telehealth COVID-19 Testing and Treatment Program

The Home Test to Treat initiative partners with health departments in high-risk communities to provide free COVID-19 testing and access to antiviral treatments.

Keep Reading

Priority 3

Discover and develop treatments

Our research identifies and tests new and existing treatments for COVID-19 and Long COVID.

Featured Initiative

Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)

The ACTIV public-private partnership evaluates the most promising potential treatments for COVID-19.

Featured Story

COVID-19 treatment materials

Antiviral Treatment Reduces Likelihood of Severe Illness From Omicron

Researchers have found that Paxlovid is effective at preventing severe COVID-19 resulting from infection by the Omicron variant of SARS-CoV-2.

Keep Reading

Priority 4

Develop vaccines to improve protection and prevention

We played an important role in the early testing and development of several vaccines, including the Moderna mRNA vaccine, and we continue to support research to prevent the spread of infection.

Featured Initiative

Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)

ACTIV has accelerated the clinical testing and evaluation of the most promising COVID-19 vaccines for approval.

Featured Story

Woman in scrubs and face shield delivers vaccination to man in face mask

mRNA Vaccine Technology: A Promising Idea for Fighting HIV

Scientists are studying the potential of mRNA vaccines to fight other diseases, including other coronaviruses, malaria, influenza, and cancer.

Keep Reading

Priority 5

Understand the risk to and provide support for people at higher risk of infection

Our programs and research aim to help people at higher risk for infection, including immunocompromised people and people from underserved communities, to prevent and treat SARS-CoV-2 infection.

Featured Initiatives

Featured Story

Hardeman and Polston

How COVID-19 and Community Violence Affect Mothers and Babies

A study supported by NIH investigates the toll of COVID-19 and police violence on pregnant people and babies in Black communities.

Keep Reading